#1 Clinical Trials Search in Europe

Df1001

DF1001 is an innovative immunotherapy drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, focusing on the drug’s potential to target natural killer (NK) cells and T-cell activation signals in various types of cancer, including lung, breast, and gastric cancers. The trials aim to assess the safety, effectiveness, and optimal dosing of DF1001, both as a standalone treatment and in combination with other cancer therapies.

Table of Contents

What is DF1001?

DF1001 is a new type of medicine being studied for the treatment of various types of solid tumors in adults[1]. It belongs to a class of drugs called immunotherapies, which work by helping your body’s immune system fight cancer. DF1001 is currently being tested in clinical trials to determine if it’s safe and effective for patients with advanced or metastatic solid tumors (cancers that have spread to other parts of the body)[1].

How DF1001 Works

DF1001 is designed to target and activate two important components of your immune system: natural killer (NK) cells and T-cells[1]. These cells are crucial in fighting cancer. The drug works by sending activation signals to these immune cells, directing them to attack specific receptors on cancer cells. One of the main targets is a protein called human epidermal growth factor receptor 2 (HER2), which is found on some types of cancer cells[1].

Conditions Treated by DF1001

DF1001 is being studied for the treatment of various types of solid tumors in adults. The clinical trial is focusing on several specific cancer types, including:

  • Non-small cell lung cancer (NSCLC) with HER2 activation[1]
  • Metastatic breast cancer, including:
    • HER2-positive breast cancer
    • HER2-low breast cancer
    • Hormone receptor (HR) positive, HER2-negative breast cancer[1]
  • Urothelial bladder cancer[1]
  • Gastric cancer (stomach cancer) with HER2 expression[1]
  • Esophageal cancer with HER2 expression[1]
  • Other solid tumors with ERBB2 amplification (ERBB2 is the gene that produces HER2 protein)[1]

Clinical Trial Details

The clinical trial for DF1001 is divided into two main phases:

  1. Dose Escalation Phase: This initial phase aims to find the safest and most effective dose of DF1001. Patients with various types of solid tumors that express HER2 will be enrolled in this phase[1].
  2. Dose Expansion Phase: Once the best dose is determined, this phase will test DF1001 in specific groups of patients with different types of cancer[1].

DF1001 in Combination Therapies

In addition to being tested as a standalone treatment (monotherapy), DF1001 is also being studied in combination with other cancer drugs. These combinations include:

  • DF1001 + Nivolumab: Nivolumab is another type of immunotherapy that works by blocking a protein called PD-1, which can help T-cells kill cancer cells more effectively[1].
  • DF1001 + Nab-paclitaxel: Nab-paclitaxel is a chemotherapy drug that combines paclitaxel (a common cancer drug) with albumin (a protein found in blood) to help deliver the medicine to cancer cells[1].
  • DF1001 + Sacituzumab govitecan-hziy: This is a complex drug that combines an antibody targeting a protein called Trop-2 (found on many cancer cells) with a chemotherapy drug[1].

Safety and Efficacy Assessment

The clinical trial is designed to evaluate several important aspects of DF1001:

  • Safety: Researchers will closely monitor patients for any side effects or adverse reactions to the drug[1].
  • Efficacy: The trial will measure how well DF1001 works in treating cancer. This includes assessing:
    • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment[1].
    • Duration of response (DOR): How long the cancer remains controlled after treatment[1].
    • Progression-free survival (PFS): How long patients live without their cancer getting worse[1].
    • Overall survival (OS): How long patients live after starting treatment[1].
  • Pharmacokinetics: How the drug moves through and is processed by the body[1].
  • Immunogenicity: Whether the body develops an immune response to the drug itself[1].
Aspect Details
Drug Name DF1001
Type of Drug Immunotherapy targeting NK cells and T-cell activation signals
Cancer Types Studied Various solid tumors, including lung, breast, gastric, esophageal, and bladder cancers
Study Phases Phase I/II
Treatment Approaches Monotherapy and combination therapy with nivolumab, nab-paclitaxel, or sacituzumab govitecan-hziy
Primary Outcomes Safety assessment, overall response rate, adverse events
Secondary Outcomes Pharmacokinetics, immunogenicity, overall survival, duration of response, progression-free survival
Study Duration Up to 2 years after last treatment for some outcomes

FAQ

  • What is DF1001 and how does it work? DF1001 is a new immunotherapy drug that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. It aims to enhance the body's immune response against solid tumors.
  • What types of cancer are being studied in the DF1001 clinical trials? The clinical trials are focusing on various solid tumors, including non-small cell lung cancer, breast cancer (HER2 positive and negative), gastric cancer, esophageal cancer, and urothelial bladder cancer.
  • Is DF1001 being tested alone or in combination with other drugs? DF1001 is being tested both as a standalone treatment (monotherapy) and in combination with other drugs such as nivolumab, nab-paclitaxel, and sacituzumab govitecan-hziy.
  • What are the main goals of the DF1001 clinical trials? The main goals are to assess the safety, tolerability, and effectiveness of DF1001. This includes determining the optimal dose, evaluating side effects, and measuring how well the drug works in treating various types of cancer.
  • How long do the DF1001 clinical trials last? The duration of the trials varies, but some outcomes are measured for up to 24 months after the start of treatment. Overall survival is assessed for up to 2 years after the last treatment.

Ongoing Clinical Trials on Df1001

  • Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France The Netherlands

Glossary

  • Solid Tumor: A mass of abnormal cells that doesn't contain cysts or liquid areas. Solid tumors can occur in various parts of the body, such as the breast, lung, or prostate.
  • HER2: Human Epidermal Growth Factor Receptor 2, a protein that promotes the growth of cancer cells. Some cancers, particularly breast cancers, can have high levels of HER2.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer. DF1001 is an example of an immunotherapy drug.
  • Natural Killer (NK) cells: A type of white blood cell that plays a crucial role in the body's immune defense against cancer and viral infections.
  • Monotherapy: Treatment using a single drug.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Dose Escalation: A method in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.

References